Wassim Nashabeh of Genentech Joins the Editorial Advisory Board of BioPharm International

Article

Wassim Nashabeh, PhD, the global head of technical regulatory policy and strategy at Genentech, has joined the Editorial Advisory Board of BioPharm International.

Wassim Nashabeh, PhD, the global head of technical regulatory policy and strategy at Genentech, has joined the Editorial Advisory Board of BioPharm International.

Wassim Nashabeh received his PhD in analytical chemistry from Oklahoma State University in 1993, and his post-doctoral fellowship from the Barnett Institute of Chemical and Biological Analysis at Northeastern University, where he developed new approaches for the separation of closely related recombinant protein variants. He joined PerSeptive Biosystems as a senior scientist from 1994–1996, where he codeveloped new schemes for antibody modification with fluorescent and enzymatic labels for use in microfabricated chip-based immunoassays.

In 1996, Nashabeh joined Genentech (A member of the Roche Group) as a scientist, and has since held several positions of increasing responsibilities, most recently global head of technical regulatory policy and strategy for the Roche Pharma Group. His current responsibilities include the development of global innovative regulatory strategies.

Nashabeh is a member of the expert working group for the International Committee on Harmonization representing the BIO organization on quality topics. He also is a member of the Board of Directors of CASSS, co-founder and chair of the International Symposium of CE in the Pharmaceutical and Biotechnology Industries, a permanent committee member of the CMC Strategy Forum conference series, co-founder of the CMC Forum Europe Conference Series, and a member of the program committee for the WCBP conference series.

Recent Videos
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.